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Abstract
Background: Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) mainly expressed in adipocytes is secreted and acts
as an adipokine. Increased circulating FABP4 level is associated with obesity, insulin resistance and atherosclerosis.
However, little is known about the modulation of serum FABP4 level by drugs including anti-dyslipidemic agents.
Methods: Patients with dyslipidemia were treated with omega-3 fatty acid ethyl esters (4 g/day; n = 14) containing
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks. Serum FABP4 level was measured before
and after treatment. Expression and secretion of FABP4 were also examined in mouse 3T3-L1 adipocytes treated
with EPA or DHA.
Results: Treatment with omega-3 fatty acid ethyl esters significantly decreased triglycerides and serum FABP4 level
(13.5 ± 1.5 vs. 11.5 ± 1.1 ng/ml, P = 0.017). Change in FABP4 level by omega-3 fatty acids was negatively correlated
with change in levels of EPA + DHA (r = −0.643, P = 0.013), EPA (r = −0.540, P = 0.046) and DHA (r = −0.650, P = 0.011)
but not change in the level of triglycerides or other fatty acid composition. Treatment of 3T3-L1 adipocytes with
EPA or DHA had no effect on short-term (2 h) secretion of FABP4. However, gene expression and long-term (24 h)
secretion of FABP4 were significantly reduced by treatment with EPA or DHA.
Conclusions: Omega-3 fatty acids decrease circulating FABP4 level, possibly by reducing expression and
consecutive secretion of FABP4 in adipocytes. Reducing FABP4 level might be involved in suppression of
cardiovascular events by omega-3 fatty acids.
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Background
Fatty acid-binding proteins (FABPs) are predominantly
cytosolic proteins that bind hydrophobic ligands, such
as long chain fatty acids [1–3]. It has been proposed
that FABPs promote the transport of fatty acids to
several organelles in the cell [1]. Fatty acid-binding
protein 4 (FABP4), also referred to as adipocyte FABP
(A-FABP) or aP2, is expressed in adipocytes and mac-
rophages. Previous studies using FABP4-deficient mice
have demonstrated that FABP4 plays important roles
in the development of insulin resistance, diabetes
mellitus and atherosclerosis [4–7], and chemical
inhibition of FABP4 might be a novel therapeutic
agent against insulin resistance, diabetes mellitus and
atherosclerosis [8].
It has recently been shown that FABP4 is secreted
from adipocytes via a non-classical secretion pathway
during lipolysis [9–12], though the sequence of FABP4
lacks signal peptides [1]. Furthermore, FABP4 has been
demonstrated to act as an adipokine for the develop-
ment of insulin resistance in liver [10], suppression of
cardiomyocyte contraction [13], inhibition of endothelial
nitric oxide synthase in endothelial cells [14] and
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proliferation and migration of vascular smooth muscle
cells [15]. It has also been shown that an elevated serum
level of FABP4 is associated with obesity, insulin resist-
ance, hypertension, cardiac dysfunction, atherosclerosis
and cardiovascular events [9, 16–23]. However, little is
known about the alteration of FABP4 level by drugs in-
cluding anti-dyslipidemic agents.
It has been reported that atorvastatin, a cholesterol-
lowering statin, decreases FABP4 level [24]. Further-
more, omega-3 fatty acids have been reported to inhibit
adipocyte differentiation and lipid accumulation in vitro,
possibly leading to a decrease in the expression of
FABP4, also known as a differentiation marker of adipo-
cytes [25–27]. We hypothesized that modulation of lipid
levels by drugs can decrease the circulating FABP4 level.
In this study, we investigated the effect of omega-3 fatty
acid ethyl esters containing eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) on serum FABP4 level
in patients with dyslipidemia. We also examined drug-
induced regulation of the expression and secretion of
FABP4 in adipocytes in the presence or absence of lipo-
lytic stimulation.
Methods
Human study (Study 1) conformed to the principles out-
lined in the Declaration of Helsinki and was performed
with the approval of the Ethical Committee of Fujita
Health University. Written informed consent was re-
ceived from all of the subjects. Experimental procedures
for in vitro study using mouse 3T3-L1 adipocytes (Study
2) were performed with approval from the Animal Care
and Experiment Committee of Sapporo Medical
University.
Study 1: Effects of omega-3 fatty acids on serum FABP4
level
Male patients with dyslipidemia (n = 14; mean age:
40.2 ± 1.7 years) were enrolled from outpatient clinics
affiliated with Fujita Health University. Entry criteria
were no treatment with lipid-lowering agents, anti-
diabetic agents or antihypertensive agents and absence
of complications such as hepatic disease, cerebrovas-
cular or cardiovascular disease, or renal disease. Pa-
tients were treated with 4 g (2 g twice daily; after
breakfast and dinner) omega-3 fatty acid ethyl esters
containing 1,860 mg/day EPA ethyl ester and 1,500
mg/day DHA ethyl ester for 4 weeks in outpatient
clinics.
Measurements
Body mass index (BMI, kg/m2) was calculated as body
weight divided by the square of body height. Before and
after the 4-week treatment with omega-3 fatty acid ethyl
esters, blood samples were collected after an overnight
fast, and serum and plasma samples were analyzed im-
mediately or stored at −80 °C until biochemical analyses.
Serum FABP4 concentration was measured using an
enzyme-linked immunosorbent assay kit (Biovendor
R&D, Modrice, Czech Republic). Precision, accuracy and
reproducibility of the kit have been described previously
[9]. Hemoglobin A1c (HbA1c) was determined by a latex
coagulation method and was expressed in NGSP scale.
Plasma glucose and fasting plasma insulin was measured
by the glucose oxidase method and a radioimmunoassay
method, respectively. Levels of creatinine (Cr),
triglycerides, total cholesterol and high-density lipopro-
tein (HDL) cholesterol were determined by enzymatic
methods. Level of low-density lipoprotein (LDL)
cholesterol was calculated by the Friedewald equation.
The compositions of 24 fatty acids, including lauric acid
(C12:0), myristic acid (C14:0), myristoleic acid
(C14:1ω5), palmitic acid (C16:0), palmitoleic acid
(C16:1ω7), stearic acid (C18:0), oleic acid (C18:1),
linoleic acid (C18:2ω6), γ-linolenic acid (C18:3ω6), α-
linolenic acid (C18:3ω3), arachidic acid (C20:0),
eicosenoic acid (C20:1ω9), eicosadienoic acid (C20:2ω6),
eicosatetraenoic acid (C20:3ω9), dihomo-γ-linolenic acid
(C20:3ω6), arachidonic acid (C20:4ω6), EPA (C20:5ω3),
behenic acid (C22:0), erucic acid (C22:1ω9), docosate-
traenoic acid (C22:4ω6), docosapentaenoic acid
(C22:5ω3), lignoceric acid (C24:0), DHA (C22:6ω3) and
nervonic acid (C24:1ω9), were determined by using ca-
pillary gas chromatography. High-sensitivity C-reactive
protein (hsCRP) was measured by a nephelometry
method. Serum level of high-molecular weight (HMW)-
adiponectin was measured using a commercially avail-
able chemiluminescent enzyme immunoassay kit (Fujire-
bio, Tokyo, Japan). Estimated glomerular filtration rate
(eGFR), an index of renal function, was calculated by an
equation for Japanese [28]: eGFR(ml/min/1.73m2) =
194 × Cr(‐ 1.094) × age(‐ 0.287) × 0.739 (if female). HOMA-
IR, an index of insulin resistance, was calculated by the
previously reported formula: insulin (μU/ml) × glucose
(mg/dl) / 405.
Study 2: Effects of omega-3 fatty acids on expression and
secretion of FABP4 in mouse 3T3-L1 adipocytes
All biochemical reagents were obtained from Sigma-
Aldrich (St. Louis, MO) unless otherwise indicated. Pre-
adipocyte 3T3-L1 cells were purchased from Health Sci-
ence Research Resources Bank (Osaka, Japan).
Differentiation of 3T3-L1 cells into adipocytes was in-
duced as previously described [11]. Differentiated 3T3-
L1 adipocytes were stimulated for 2 h (short-term secre-
tion analysis) in the presence and absence of 10 μM iso-
proterenol or 24 h (long-term secretion and gene
expression analyses) with 0–100 μM EPA or 0–100 μM
DHA in Dulbecco’s Modified Eagle’s Medium (DMEM)
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(Invitrogen, Carlsbad, CA) supplemented with 0.5 %
fatty acid-depleted BSA. The doses of reagents and incu-
bation periods were varied according to the experimen-
tal protocol. Each experiment was performed in at least
triplicate.
Quantitative real-time PCR
Total RNA was isolated using Trizol Reagent (Invitro-
gen), and cDNA was synthesized using a kit (Applied
Biosystems, Foster City, CA). Quantitative real-time
PCR analysis using SYBR Green was performed (Applied
Biosystems). The thermal cycling program was 10 min at
95°C for enzyme activation and 40 cycles of denaturation
for 15 s at 95 °C, 30-s annealing at 58 °C and 35-s
extension at 72 °C. Two pairs of specific primers used
are as follows: 5′- AAG GTG AAG AGC ATC ATA
ACC CT -3′ and 5′- TCA CGC CTT TCA TAA
CAC ATT CC -3′ for FABP4, 5′- TCG CTG ATG
CAC TGC CTA TG -3′ and 5′- GAG AGG TCC
ACA GAG CTG ATT -3′ for peroxisome
proliferator-activated receptor (PPAR)-γ2, 5′- CAA
GAA CAG CAA CGA GTA CCG -3′ and 5′- GTC
ACT GGT CAA CTC CAG CAC -3′ for CCAAT/en-
hancer binding protein α (C/EBPα) and 5′- AGT
CCC TGC CCT TTG TAC ACA -3′ and 5′- CGA
TCC GAG GGC CTC ACT A -3′ for 18s rRNA as
an internal control gene.
Western blot analysis
The conditioned medium (CM) isolated from adipocytes
was filtered to obtain 10-50-kDa fractions of proteins
using Amicon Ultra 10K and 50K devices (Millipore, Bil-
lerica, MA). For lysing cells, a cell lysis buffer, containing
50 mM Tris–HCl (pH 7.0), 5 mM EDTA, 2 mM EGTA,
10 mM Na4P2O7, 10 mM Na3VO4, 40 mM β-
glycerophosphate, 30 mM NaF, 0.5 % NP-40, and 1 %
protease inhibitor cocktail, was used. Total protein con-
tent of the cell lysate (CL) was assessed by a microplate
protein assay based on the Lowry method (Bio-Rad,
Hercules, CA).
Equal protein amounts per the CL and the filtered CM
were subjected to SDS–polyacrylamide gel electrophor-
esis and electrophoretically transferred onto PVDF
membranes (Whatman, Florham Park, NJ). After incu-
bation for 1 h at room temperature with a blocking solu-
tion of 3 % BSA in Tris-buffered saline buffer containing
0.1 % Tween 20 (TBST), the membranes were incubated
with primary antibodies for FABP4 (#ab13979; Abcam,
Tokyo, Japan) and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (#sc-20357; Santa Cruz Biotechnology,
Santa Cruz, CA) overnight at 4 °C. After washing with
TBST, the membranes were incubated with a secondary
antibody conjugated with horseradish peroxidase (Santa
Cruz Biotechnology) for 1 h at room temperature and
washed. Immunodetection was performed using a
chemiluminescence kit (Roche Diagnostics, Tokyo,
Japan). Densitometry analysis was performed using Ima-
geJ software. FABP4 secretion was expressed as densi-
tometry of FABP4 in the CM divided by those of FABP4
in the CL and GAPDH in the CL as previously described
[29].
Statistical analysis
Numeric variables are expressed as means ± SEM. For
regression analyses, the distribution normality of each
parameter was checked using the Shapiro-Wilk W test,
and non-normally distributed parameters were logarith-
mically transformed. The correlation between two pa-
rameters was evaluated using Pearson’s correlation
coefficient. Comparison between paired samples was
done with Wilcoxon signed-rank test. For detecting sig-
nificant differences in data between more than two
groups, one-way analysis of variance and Tukey-Kramer
post hoc test were used. A p value of less than 0.05 was
considered statistically significant. All data were analyzed
by using JMP 9 for Macintosh (SAS Institute, Cary, NC).
Results
Study 1
Characteristics of the patients are shown in Table 1. No
one dropped out from the protocol in Study 1.
Treatment with omega-3 fatty acid ethyl esters for 4
weeks significantly decreased triglycerides (163.7 ± 20.6
vs. 98.1 ± 11.4 mg/dl, P = 0.003), but no significant
Table 1 Characteristics of the male patients (Omega-3 FAs, 4w)
Pre Post
n 14
Age (years) 40.2 ± 1.7
Body mass index (kg/m2) 25.9 ± 0.7 26.1 ± 0.7
Waist circumference (cm) 89.5 ± 1.8 89.0 ± 2.0
Biochemical data
Total cholesterol (mg/dl) 217.2 ± 7.1 207.6 ± 8.5
HDL cholesterol (mg/dl) 57.6 ± 3.7 57.6 ± 4.3
LDL cholesterol (mg/dl) 132.6 ± 6.5 125.8 ± 8.3
Triglycerides (mg/dl) 163.7 ± 20.6 98.1 ± 11.4*
Glucose (mg/dl) 97.6 ± 2.2 98.0 ± 1.8
Insulin (μU/ml) 7.9 ± 1.9 6.5 ± 1.2
HOMA-IR 1.99 ± 0.56 1.57 ± 0.28
HbA1c (%) 5.5 ± 0.1 5.5 ± 0.1
hsCRP (mg/dl) 0.60 ± 0.17 0.75 ± 0.20
HMW-adiponectin (μg/ml) 2.42 ± 0.23 2.31 ± 0.23
FABP4 (ng/ml) 13.5 ± 1.5 11.5 ± 1.1*
Variables are expressed as n or means ± SEM
hsCRP high-sensitivity C-ractive protein, HMW high-molecular weight
*P <0.05 vs. Pre
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differences were found before and after treatment in
waist circumference, BMI or levels of glucose, insulin,
HOMA-IR, total cholesterol, LDL cholesterol, HDL
cholesterol, hsCRP or HMW-adiponectin. Regarding
fatty acid composition, treatment with omega-3 fatty
acid ethyl esters significantly increased EPA (48.6 ± 5.3
vs. 144.6 ± 12.4 μg/ml, P < 0.001), DHA (139.8 ± 8.2 vs.
179.5 ± 7.6 μg/ml, P < 0.001), behenic acid and docosa-
pentaenoic acid and conversely decreased palmitic acid,
palmitoleic acid, oleic acid, linoleic acid, γ-linolenic acid,
eicosadienoic acid, eicosatetraenoic acid, dihomo-γ-
linolenic acid, arachidonic acid, docosatetraenoic acid
and total fatty acids (Table 2). Serum FABP4 level was
significantly decreased by 14.8 % after treatment with
Table 2 Fatty acid composition (Omega-3 FAs, 4w)
μg/ml %vol
Pre Post Pre Post
Saturated fatty acids
Lauric acid C12:0 5.4 ± 0.9 3.4 ± 0.6 0.16 ± 0.02 0.12 ± 0.02
Myristic acid C14:0 31.0 ± 4.2 20.7 ± 2.2 0.89 ± 0.09 0.71 ± 0.06
Palmitic acid C16:0 607.5 ± 40.8 491.0 ± 18.3* 17.7 ± 0.4 17.0 ± 0.3
Stearic acid C18:0 304.6 ± 20.0 265.2 ± 11.0 8.9 ± 0.3 9.2 ± 0.2
Arachidic acid C20:0 2.0 ± 0.2 1.6 ± 0.1 0.058 ± 0.004 0.055 ± 0.004
Behenic acid C22:0 1.1 ± 0.1 1.9 ± 0.2* 0.0077 ± 0.0077 0.092 ± 0.014*
Lignoceric acid C24:0 0.81 ± 0.06 0.75 ± 0.03 0.025 ± 0.001 0.027 ± 0.002
Monounsaturated fatty acids
Myristoleic acid C14:1ω5 3.0 ± 0.6 1.4 ± 0.2* 0.083 ± 0.016 0.048 ± 0.006
Palmitoleic acid C16:1ω7 66.2 ± 6.8 42.2 ± 3.9* 1.9 ± 0.1 1.4 ± 0.1*
Oleic acid C18:1ω9 749.7 ± 66.9 526.7 ± 36.5* 21.6 ± 0.9 18.0 ± 0.6*
Eicosenoic acid C20:1ω9 6.0 ± 0.7 5.3 ± 0.6 0.17 ± 0.01 0.18 ± 0.02
Erucic acid C22:1ω9 3.4 ± 0.2 3.3 ± 0.1 0.10 ± 0.01 0.11 ± 0.01
Nervonic acid C24:1ω9 1.9 ± 0.1 1.9 ± 0.1 0.060 ± 0.048 0.068 ± 0.005
Polyunsaturated fatty acids
Omega-3 fatty acids
α-Linolenic acid C18:3ω3 26.9 ± 2.7 22.3 ± 2.8 0.78 ± 0.05 0.75 ± 0.07
Eicosapentaenoic acid (EPA) C20:5ω3 48.6 ± 5.3 144.6 ± 12.4* 1.5 ± 0.2 5.0 ± 0.6*
Docosapentaenoic acid C22:5ω3 19.8 ± 1.2 25.7 ± 1.4* 0.59 ± 0.04 0.90 ± 0.05*
Docosahexaenoic acid (DHA) C22:6ω3 139.8 ± 8.2 179.5 ± 7.6* 4.2 ± 0.3 6.4 ± 0.4*
Omega-6 fatty acids
Linoleic acid C18:2ω6 1064.3 ± 46.2 894.0 ± 54.3* 31.6 ± 0.9 30.6 ± 1.1
γ-linolenic acid C18:3ω6 11.0 ± 1.5 6.4 ± 1.0* 0.32 ± 0.04 0.22 ± 0.03*
Eicosadienoic acid C20:2ω6 6.9 ± 0.5 4.7 ± 0.3* 0.20 ± 0.01 0.16 ± 0.01*
Dihomo-γ-linolenic acid C20:3ω6 47.2 ± 3.4 27.4 ± 3.1* 1.4 ± 0.1 1.0 ± 0.1*
Arachidonic acid (AA) C20:4ω6 248.0 ± 14.8 222.4 ± 12.1* 7.5 ± 0.4 7.8 ± 0.3
Docosatetraenoic acid C22:4ω6 4.7 ± 0.3 2.8 ± 0.2* 0.14 ± 0.01 0.10 ± 0.01*
Omega-9 fatty acids
Eicosatetraenoic acid C20:3ω9 1.5 ± 0.1 1.1 ± 0.1* 0.045 ± 0.002 0.035 ± 0.002*
Total fatty acids 3402.8 ± 181.2 2899.1 ± 120.0* 100 100
Calculation
EPA/AA 0.20 ± 0.02 0.68 ± 0.07*
DHA/AA 0.57 ± 0.03 0.83 ± 0.04*
EPA + DHA 188.4 ± 12.2 324.2 ± 18.6* 5.7 ± 0.5 11.4 ± 1.0*
(EPA + DHA)/AA 0.78 ± 0.05 1.50 ± 0.11*
Variables are expressed as n or means ± SEM. *P <0.05 vs. Pre
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omega-3 fatty acid ethyl esters (13.5 ± 1.5 vs. 11.5 ± 1.1
ng/ml, P = 0.017) (Fig. 1a). Change (Post - Pre) in FABP4
level was negatively correlated with change in levels of
EPA +DHA (r = −0.643, P = 0.013) (Fig. 1b), EPA (r =
−0.540, P = 0.046) (Fig. 1c) and DHA (r = −0.650, P =
0.011) (Fig. 1d). However, change in FABP4 level
was not correlated with change in levels of total
fatty acids (r = −0.003, P = 0.911) (Fig. 1e), triglycer-
ides (r = −0.019, P = 0.948) (Fig. 1f ) or other fatty
acid composition.
Study 2
Treatment with both EPA and DHA for 24 h signifi-
cantly decreased gene expression of FABP4 in 3T3-L1
adipocytes in a dose-dependent manner, and the effect
tended to be more augmented with DHA treatment than
with EPA treatment (Fig. 2a, b). Furthermore, both EPA
and DHA significantly decreased gene expression of
PPARγ2 and C/EBPα in 3T3-L1 adipocytes in a dose-
dependent manner (Fig. 2c-f). Western blot analysis
showed that FABP4, but not a non-secretory protein
GAPDH, was present in the CM of 3T3-L1 (Fig. 2g, h),
indicating that FABP4 is secreted from adipocytes with-
out cell destruction. FABP4 secretion was induced by
lipolytic stimulation with 10 μM isoproterenol, a pan-β-
adrenergic agonist, for 2 h (Fig. 2g) as previously
reported [11]. Treatment with 50 μM EPA or 50 μM
DHA for 2 h (short-term) did not significantly change
FABP4 secretion from adipocytes in the absence or pres-
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Fig. 1 Effect of omega-3 fatty acid ethyl esters on FABP4 level (Study 1). a. Treatment with 4 g (2 g twice daily) omega-3 fatty acid ethyl esters,
containing 1,860 mg/day eicosapentaenoic acid (EPA) ethyl ester and 1,500 mg/day docosahexaenoic acid (DHA) ethyl ester, for 4 weeks significantly
decreased FABP4 levels in male patients with hypertriglycemia (n = 14). *P < 0.05. b-d. Changes (Post – Pre) in levels of EPA + DHA (b), EPA (c), DHA (d),
total fatty acids (e) and triglycerides (f) were plotted against change in level of FABP4 for each subject
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significant decrease of FABP4 secretion from adipocytes
was observed at 24 h (long-term) after treatment with
50 μM EPA or 50 μM DHA (Fig. 2h).
Discussion
The present study demonstrated for the first time that
treatment with omega-3 fatty acid ethyl esters containing
EPA and DHA for 4 weeks significantly decreased serum
FABP4 concentration in patients with dyslipidemia.
Furthermore, in vitro experiments showed that treat-
ment with EPA or DHA dose-dependently (up to 100
μM) decreased the expression and consecutive long-
term secretion, but not short-term secretion, of FABP4
in 3T3-L1 adipocytes. Average changes in the levels of
EPA and DHA by treatment with omega-3 fatty acid
ethyl esters were 96.0 μg/ml (317 μM) and 39.7 μg/ml
(121 μM), respectively, in the present study, indicating
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Fig. 2 Gene expression and secretion of FABP4 in 3T3-L1 adipocytes treated with omega-3 fatty acids (Study 2). a, b. Gene expression of FABP4
was determined by quantitative real-time PCR in differentiated 3T3-L1 adipocytes treated with 0–100 μM eicosapentaenoic acid (EPA) (A) or
0–100 μM docosahexaenoic acid (DHA) (B) for 24 h (n= 3 in each group). *P < 0.05 vs. 0 μM. c-f. Gene expression of peroxisome proliferator-activated
receptor γ2 (PPARγ2) and CCAAT/enhancer binding protein α (C/EBPα) was determined by quantitative real-time PCR in differentiated 3T3-L1 adipocytes
treated with 0–100 μM EPA (c, d) or 0–100 μM DHA (E, F) for 24 h (n= 6 in each group). *P< 0.05 vs. 0 μM. g. Western blot analysis of FABP4 and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using the cell lysate (CL) and conditioned medium (CM) of 3T3-L1 adipocytes treated with 50 μM
EPA or 50 μM DHA in the absence and presence of 10 μM isoproterenol for 2 h (n= 5 in each group). n.s., not significant. h. Western blot analysis of
FABP4 and GAPDH using the CL and CM of 3T3-L1 adipocytes treated with 50 μM EPA or 50 μM DHA for 24 h (n = 5 in each group). FABP4 secretion
was relatively expressed as densitometry of FABP4 in the CM divided by those of FABP4 in the CL and GAPDH in the CL. AU, arbitrary unit. *P < 0.05 vs.
Fatty acid (−)
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were physiological but not pharmacological. These find-
ings suggest that a direct suppressive effect of omega-3
fatty acids on FABP4 expression and its consecutive se-
cretion in adipocytes plays a role in the decrease in
serum FABP4 level.
In the present study, treatment with omega-3 fatty
acid ethyl esters significantly decreased triglycerides and
total fatty acids and modulated levels of fatty acid com-
position. However, changes in the levels of triglycerides,
total fatty acids and each fatty acid composition except
for EPA and DHA were not correlated with reduction of
FABP4 level, suggesting that qualitative, but not quanti-
tative, change in fatty acids contributes to the reduction
in FABP4 concentration. It has been reported that ex-
pression of FABP4 in adipocytes is up-regulated by
PPARγ agonists and saturated and monounsaturated
fatty acids [1, 2, 30–32]. On the other hand, polyunsat-
urated fatty acids, such as omega-3 fatty acids, have been
reported to inhibit adipocyte differentiation and lipid ac-
cumulation, leading to a decrease in the expression of
FABP4, also known as an adipocyte differentiation
marker [25–27]. Furthermore, it has been shown that
unsaturated fatty acids, including EPA, repress expres-
sion of FABP4 in RAW264.7 macrophages [33], though
the predominant contributors of circulating FABP4 are
adipocytes rather than macrophages [10]. In the present
study, we showed that both EPA and DHA decreased
FABP4 expression even in differentiated 3T3-L1 adipo-
cytes, at least in part, via reduction in gene expression of
PPARγ2 and C/EBPα, which are critical transcription
factors for regulation of adipocyte differentiation [34].
There have been some reports about modulation of
FABP4 concentration by drugs. Atorvastatin, a
cholesterol-lowering statin, has been reported to de-
crease FABP4 level, but the mechanism is totally un-
known [24]. It has also been shown that several
angiotensin II receptor blockers (ARBs) decrease circu-
lating FABP4 concentration [29, 35], and reduction of
sympathetic nerve activation due to a class effect of
ARBs, but not a direct effect of angiotensin II receptor
blockade, has been postulated as a possible mechanism
of decreased FABP4 level by ARBs [29], since FABP4 se-
cretion from adipocytes is associated with β-adrenergic
receptor-mediated lipolysis [10, 11]. Previous studies
showed that dietary fish and omega-3 fatty acid con-
sumption decreased sympathetic nerve activity [36, 37].
Other than direct suppressive effects of EPA and DHA
on FABP4 expression in adipocytes, treatment with
omega-3 fatty acid ethyl esters containing EPA and
DHA may decrease FABP4 concentration by inhibiting
FABP4 secretion from adipocytes associated with sympa-
thetic tone-mediated lipolysis.
Previous studies including a recent meta-analysis have
shown that both dietary and circulating EPA and DHA
are associated with the low incidence of cardiovascular
disease in a multiethnic population [38, 39]. Further-
more, recent clinical trials have demonstrated that
omega-3 fatty acids, including EPA alone, EPA +DHA
and fish oil, substantially reduce cardiovascular events
[40–43]. Since there is accumulating evidence demon-
strating significant roles of circulating FABP4 in insulin
resistance, atherosclerosis and cardiovascular events [10,
14, 15, 17, 21–23], the results of the present study sup-
port the notion that reduction of FABP4 concentration
is one of the important mechanisms by which omega-3
fatty acids prevent the development of cardiovascular
disease.
The present study has several limitations. The num-
ber of patients recruited in Study 1 was small, and
the possibility of a type 1 error cannot be excluded.
Since it has been reported that there is a gender dif-
ference in serum FABP4 levels [9, 18], we recruited
only male patients to reduce confounding factors.
The present study also lacked a placebo control
group. Interventional studies of placebo-control de-
sign using larger numbers of both male and female
patients are necessary for evaluating the impact of
omega-3 fatty acids on circulating FABP4 level. Fur-
thermore, mouse 3T3-L1 adipocytes, a well-used cell
line of adipocytes, were used in vitro experiments,
but there might be a difference between mice and
humans in regulation of the expression and secretion
of FABP4 by omega-3 fatty acids. Lastly, there has
been accumulating evidence indicating FABP4 is
expressed in several types of cells, in addition to adi-
pocytes and macrophages, under both physiological
and pathological conditions [2, 3, 44–48]. Omega-3
fatty acids may affect the expression and secretion of
FABP4 in cells other than adipocytes, though the pre-
dominant contributors of circulating FABP4 level are
adipocytes rather than macrophages and other cells
[3, 10].
Conclusions
Treatment with omega-3 fatty acid ethyl esters contain-
ing EPA and DHA decreases serum FABP4 concentra-
tion in patients with dyslipidemia, at least in part, via a
direct reduction in expression and consecutive secretion
of FABP4 in adipocytes. Suppression of FABP4 levels
may lead to the reduction of cardiovascular events as a
pleiotropic effect of supplements of omega-3 fatty acids.
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